Denali Therapeutics Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $394.9M | $79.4M |
| FY2020 | — | $1.15B | $507.1M |
| FY2021 | — | $962.3M | $293.5M |
| FY2022 | — | $1.04B | $218.0M |
| FY2023 | — | $1.03B | $127.1M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $394.9M | $79.4M |
| FY2020 | — | $1.15B | $507.1M |
| FY2021 | — | $962.3M | $293.5M |
| FY2022 | — | $1.04B | $218.0M |
| FY2023 | — | $1.03B | $127.1M |